November 10, 2015.
Reuters reports
that Dr Reddy's Laboratories Ltd, India's second-largest drugmaker, has received a warning letter from FDA over inadequate quality controls at three manufacturing plants producing drugs for cancer and other diseases. Dr Reddy's will not receive US approvals for drugs made at the plants until it the problems have been resolved. The affected plants reportedly account for 10 percent to 12 percent of the company's sales. Dr Reddy's said a production halt may not be required, but they were "surprised" by the news, with shares dropping to a four-month low. Dr Reddy's Chief Executive G V Prasad said the group was now revamping its quality systems.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.